Biotech Values

[acgood]

HSP90

I agree this is a very promising target, but has been marred by toxicity problems with many inhibitor candidates. If you are looking into the various competitors, here is the run-down:

Single-agent responses have been reported
ganetespib aka STA-9090 from SNTA - phase 2b data 2q2012
retaspamycin HCl aka IPI-504 from INFI - in phase 2 but no data in 2012

Phase 1 results coming by ASCO 2012 - claims of good safety and PRs have been made
AT13387 from ASTX
Debio0932 from CRIS/DebioPharm

Phase 1 reported with ocular toxicity issues or otherwise abandoned
MPC-3100 from MYRX
AUY922 from NVS/Vernalis
BIIB021 and BIIB028 from BIIB
SNX5422 from PFE
XL888 from EXEL

I started to assemble info on these programs here...you'll find trial info and some abstracts, but it is admittedly incomplete:
http://goo.gl/tGXuV